Based in the United States, Anagin is a startup.
Anagin develops novel targeted therapies addressing synaptic plasticity disruptions in the central nervous system to treat neuropsychiatric disorders such as PTSD, depression, neuropathic pain, Alzheimer's, and Parkinson's disease.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.